Inflammatory Bowel Diseases: Collaborating for Improved Access to Quality Care
Jointly provided by

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Inflammatory Bowel Diseases: Collaborating for Improved Access to Quality Care

Webcasts Now Concluded

Wednesday, September 23, 2020   |   1:00 PM - 2:30 PM ET

Monday, September 28, 2020*   |   12:00 PM - 1:30 PM ET

Last year payers and providers in cities across the country convened to identify opportunities to collaboratively address the clinical and economic burden of IBD in plan populations. Get up-to-date information on IBD and learn about their findings at this live CE event.

Don't miss the on-demand CE associated with these webcasts:
Inflammatory Bowel Diseases Clinical Primer and Care Pathway Tool Kit
  • Improving clinical & economic outcomes for payers by providing appropriate access to IBD treatment options
  • Integrating IBD care pathways into plan infrastructure
  • Employing decision-support tools for member benefit design
Peter D.R. Higgins, MD, PhD, MSc (CRDSA)
Professor, Division of Gastroenterology
Director, IBD Program
Director, Ambulatory and Chronic Disease Clinical Trial Support Unit
Department of Internal Medicine
University of Michigan
Vanita Pindolia, PharmD, MBA
Vice President
Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System (HFHS)
Health Alliance Plans (HAP)
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, registered nurses, care managers, and other managed care and payer organization professionals

The impact of the advent of targeted biologics has not been more evident in any therapeutic category than anti-inflammatory drugs. However, the historically high cost of these agents has impelled increased management on the part of health plan stakeholders. In light of current trends toward stricter utilization management, increased member cost-share, and other initiatives that may create a barrier to patient access, managed care professionals and affiliated network providers require education on the economic burden and health care resource utilization of IBD. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in provider practice, payer stakeholders also require an influx of valuable information to effectively address the evolving paradigm of disease management.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Characterize the clinical and economic burden of IBD in terms of health care resource utilization, indirect costs, and member quality of life
  • Outline the role of various imaging studies and laboratory tests/assays in the diagnosis of IBD
  • Demonstrate how appropriate access to IBD treatment options can improve clinical and economic outcomes for payers
  • Review clinical trials and the practice guidelines utilized by academic centers for therapeutic selection in IBD
  • Integrate available IBD care pathways from professional organizations into plan infrastructure
  • Employ decision-support tools that assist payers in making fully informed choices about investing resources and designing member benefits for a proactive and personalized treatment approach among patients with IBD
Opening Comments/Overview
Crohn's & Colitis Foundation: Orna G. Ehrlich, MPH (September 23); Laura Wingate (September 28)

Welcome and Introduction
Vanita K. Pindolia, PharmD, MBA

IBD Management: Clinical Considerations from Timely Diagnosis to Effective Treatment
Peter D.R. Higgins, MD, PhD, MSc (CRDSA)

Balancing Quality and Cost in IBD Specialty Drug Management
Vanita Pindolia, PharmD, BCPS, MBA

Audience Q&A Session
Key Takeaways and Closing Comments

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Crohn's & Colitis Foundation, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-20-2288-L01-P
Type of Activity:Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Fee Information
No additional fee is required to attend this CME/CPE/CNE activity.

If you have any questions, please call (215) 619-8812 or email